JP2022519082A - 新規ｃｄ４０結合抗体 - Google Patents

新規ｃｄ４０結合抗体 Download PDF

Info

Publication number
JP2022519082A
JP2022519082A JP2021544622A JP2021544622A JP2022519082A JP 2022519082 A JP2022519082 A JP 2022519082A JP 2021544622 A JP2021544622 A JP 2021544622A JP 2021544622 A JP2021544622 A JP 2021544622A JP 2022519082 A JP2022519082 A JP 2022519082A
Authority
JP
Japan
Prior art keywords
seq
antibody
antibody according
human
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021544622A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020159368A5 (enExample
Inventor
ヨハネス・イェレ・ファン・デル・フリート
イリス・デ・ヴェールト
タニヤ・デニス・デ・グライル
ポール・パレン
アロン・フィリップ・カテル
ジョルジュ・ローデヴェイク・シェフェール
Original Assignee
ラヴァ・セラピューティクス・ベー・フェー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL2022494A external-priority patent/NL2022494B1/en
Application filed by ラヴァ・セラピューティクス・ベー・フェー filed Critical ラヴァ・セラピューティクス・ベー・フェー
Publication of JP2022519082A publication Critical patent/JP2022519082A/ja
Publication of JPWO2020159368A5 publication Critical patent/JPWO2020159368A5/ja
Priority to JP2024218893A priority Critical patent/JP2025032324A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021544622A 2019-02-01 2020-01-30 新規ｃｄ４０結合抗体 Pending JP2022519082A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024218893A JP2025032324A (ja) 2019-02-01 2024-12-13 新規ｃｄ４０結合抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL2022494 2019-02-01
NL2022494A NL2022494B1 (en) 2019-02-01 2019-02-01 Novel CD40-binding antibodies
NL2024087 2019-10-23
NL2024087 2019-10-23
PCT/NL2020/050051 WO2020159368A1 (en) 2019-02-01 2020-01-30 Novel cd40-binding antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024218893A Division JP2025032324A (ja) 2019-02-01 2024-12-13 新規ｃｄ４０結合抗体

Publications (2)

Publication Number Publication Date
JP2022519082A true JP2022519082A (ja) 2022-03-18
JPWO2020159368A5 JPWO2020159368A5 (enExample) 2022-12-27

Family

ID=71840475

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021544622A Pending JP2022519082A (ja) 2019-02-01 2020-01-30 新規ｃｄ４０結合抗体
JP2024218893A Ceased JP2025032324A (ja) 2019-02-01 2024-12-13 新規ｃｄ４０結合抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024218893A Ceased JP2025032324A (ja) 2019-02-01 2024-12-13 新規ｃｄ４０結合抗体

Country Status (11)

Country Link
US (1) US20220135694A1 (enExample)
EP (1) EP3917960A1 (enExample)
JP (2) JP2022519082A (enExample)
KR (1) KR20210141466A (enExample)
CN (1) CN113993893A (enExample)
AU (1) AU2020216250A1 (enExample)
BR (1) BR112021015238A8 (enExample)
CA (1) CA3128148A1 (enExample)
MX (1) MX2021009285A (enExample)
SG (1) SG11202108141VA (enExample)
WO (1) WO2020159368A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532807A (ja) 2020-07-08 2023-07-31 ラヴァ・セラピューティクス・エヌ・ヴイ Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体
IL300517A (en) * 2020-08-14 2023-04-01 Gammadelta Therapeutics Ltd Multispecific antibodies against variable chain delta 1 on TCR
EP4259660A1 (en) * 2020-12-10 2023-10-18 LAVA Therapeutics N.V. Antibodies that bind gamma-delta t cell receptors
JP2024506682A (ja) * 2021-02-17 2024-02-14 ガンマデルタ セラピューティクス リミテッド 抗ＴＣＲδ鎖可変部１抗体
JP2024509332A (ja) 2021-02-17 2024-02-29 ガンマデルタ セラピューティクス リミテッド 多重特異性抗ＴＣＲδ可変部１抗体
AU2022292159A1 (en) 2021-06-18 2023-12-21 Autolus Limited Anti-cd307e single-domain antibodies, uses thereof in car t-cell and for the treatment of diseases
WO2023025194A1 (zh) * 2021-08-24 2023-03-02 江苏恒瑞医药股份有限公司 Fap/cd40结合分子及其医药用途
WO2023067138A1 (en) 2021-10-21 2023-04-27 LAVA Therapeutics N.V. Uses of gamma delta t cell activating antibodies
CN119213028A (zh) * 2022-01-05 2024-12-27 印希比生物科学有限公司 结合γδ T细胞的多肽及其用途
CA3208653A1 (en) * 2022-02-17 2022-08-25 Mihriban Tuna Multispecific anti-tcr delta variable 1 antibodies
EP4292609A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
JP2025521865A (ja) * 2022-06-28 2025-07-10 ベイジン スターマブ バイオメド テクノロジ リミテッド 単特異性抗体および多重特異性抗体
CN116023495B (zh) * 2022-09-05 2023-10-03 上海百英生物科技股份有限公司 一种抗cd40纳米抗体及其制备方法与应用
WO2024092150A2 (en) * 2022-10-26 2024-05-02 Providence Health & Services - Oregon Combination therapies utilizing microbially-expanded gamma delta t cells and t cell engaging biologics
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513953A (ja) * 2011-04-21 2014-06-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃｄ４０を拮抗する抗体ポリペプチド
US20180340031A1 (en) * 2017-05-25 2018-11-29 Bristol-Myers Squibb Company Antagonistic cd40 monoclonal antibodies and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60143535D1 (de) * 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
JP2012521768A (ja) 2009-03-27 2012-09-20 ジモジェネティクス・インコーポレイテッド 抗体−受容体の組み合わせを含む多特異的結合性タンパク質を用いるための組成物および方法
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
JP5997154B2 (ja) 2010-08-16 2016-09-28 ノビミューン エスアー 多重特異性多価抗体の生成方法
CN120383672A (zh) 2012-04-20 2025-07-29 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
WO2014081202A1 (ko) 2012-11-21 2014-05-30 주식회사 파멥신 Vegfr-2와 dll4를 표적으로 하는 이중표적항체 및 이를 포함하는 약학적 조성물
EA039086B1 (ru) 2014-04-10 2021-12-01 Лава Терапьютикс Н.В. Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы
BR112019000512A2 (pt) * 2016-07-14 2019-04-24 Genmab A/S anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513953A (ja) * 2011-04-21 2014-06-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃｄ４０を拮抗する抗体ポリペプチド
US20180340031A1 (en) * 2017-05-25 2018-11-29 Bristol-Myers Squibb Company Antagonistic cd40 monoclonal antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R. C. G. DE BRUIN ET AL., ONCOIMMUNOLOGY, vol. 7:1, e1375641, JPN6023049259, 2017, pages 1 - 14, ISSN: 0005390773 *

Also Published As

Publication number Publication date
US20220135694A1 (en) 2022-05-05
MX2021009285A (es) 2021-11-12
SG11202108141VA (en) 2021-08-30
WO2020159368A1 (en) 2020-08-06
AU2020216250A1 (en) 2021-08-26
JP2025032324A (ja) 2025-03-11
KR20210141466A (ko) 2021-11-23
EP3917960A1 (en) 2021-12-08
BR112021015238A2 (pt) 2022-02-15
BR112021015238A8 (pt) 2022-08-16
CN113993893A (zh) 2022-01-28
CA3128148A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
JP2025032324A (ja) 新規ｃｄ４０結合抗体
JP7581420B2 (ja) 抗ｔｉｇｉｔ抗体並びに治療剤及び診断剤としてのその使用
US12077586B2 (en) Bispecific antibodies for use in the treatment of hematological malignancies
JP7290013B2 (ja) Ｐｄ－ｌ１およびｃｄ１３７に結合する結合物質ならびにその使用
JP7293121B2 (ja) Ｐｄ－ｌ１に対する抗体
RU2608644C2 (ru) Антитела против белка рецептора с-мет
US11130819B2 (en) Antibodies
CN108495864A (zh) 抗ror1抗体、ror1×cd3双特异性抗体及其使用方法
CN113906054B (zh) 能够结合cd19和cd3的多特异性抗原结合蛋白及其用途
JP2024530451A (ja) 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体及び応用
JP2023532807A (ja) Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体
JP2024507937A (ja) Ｃｄ１２３及びガンマデルタｔ細胞受容体に結合する抗体
JP7503215B2 (ja) Ｃｄ３０及びｃｄ３に結合する抗体
NL2022494B1 (en) Novel CD40-binding antibodies
JP7791229B2 (ja) 抗体
RU2852877C2 (ru) Антитела
CN117255804A (zh) 针对人4-1bb的抗体及其变体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240521

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240813